[go: up one dir, main page]

EP2262485A1 - Composition à libération modifiée comprenant de la doxofylline - Google Patents

Composition à libération modifiée comprenant de la doxofylline

Info

Publication number
EP2262485A1
EP2262485A1 EP09721101A EP09721101A EP2262485A1 EP 2262485 A1 EP2262485 A1 EP 2262485A1 EP 09721101 A EP09721101 A EP 09721101A EP 09721101 A EP09721101 A EP 09721101A EP 2262485 A1 EP2262485 A1 EP 2262485A1
Authority
EP
European Patent Office
Prior art keywords
composition
doxofylline
cellulose
magnesium stearate
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09721101A
Other languages
German (de)
English (en)
Inventor
Frederick Van Gulik
Madhusudan Rao Yamsani
Ramesh Gannu
Suresh Bandari
Bodapunti Prabha Shankar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eurodrug Laboratories BV
Original Assignee
Eurodrug Laboratories BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurodrug Laboratories BV filed Critical Eurodrug Laboratories BV
Publication of EP2262485A1 publication Critical patent/EP2262485A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Definitions

  • the present invention concerns a new pharmaceutical composition
  • doxofylline in particular a modified release formulation, for administration once a day only.
  • Doxofylline (7-(l,3-dioxalan-2-ylmethyl)-theophylline) is a drug derived from theophylline which is used in therapy as a bronchodilator, with anti-inflammatory action, in reversible airway obstruction. It is commonly administered in doses ranging from 800 to 1200 mg per day, orally, according to a dosage which provides for the intake of two to three dosage units per day in order to maintain therapeutically effective haematic levels.
  • the doxofylline tablets commercially available generally contain 400 mg of active ingredient and release almost all the drug within one hour from intake. The half- life of the drug is around 6-7 hours and for this reason several administrations are required during the 24-hour period.
  • dosage units containing 400 mg of active ingredient are currently administered two/three times a day for a daily average of approximately 1000 mg of active ingredient, a dosage considered necessary to maintain the therapeutic haematic levels of doxofylline.
  • Such a dosage unit is currently marketed by Dr. Reddy's Laboratories Ltd as DOXOBID and has the following quali-quantitative composition: doxofylline (400 mg), colloidal silicon dioxide (13 mg), corn starch (63 mg), mannitol (40 mg), povidone (7 mg), microcrystalline cellulose (64 mg), talc (30 mg), magnesium stearate (3 mg) and water (0.08 ml).
  • a further object of the present invention is to provide a composition of doxofylline which lowers the initial haematic peak and the first-pass effect occurring in the conventional compositions.
  • a further object of the present invention is to provide a doxofylline composition which maintains the effective concentration of the drug in the blood sufficient to exert the bronchodilatory and anti-inflammatory effect over the 24-hour period, thus reducing the risk of bronchospasm and serious consequences for the patient.
  • Another object of the present invention is to provide a modified release doxofylline composition which avoids the need for recourse to rescue medication, such as salbutamol inhalers, to overcome acute asthmatic attacks and bronchospasms.
  • rescue medication such as salbutamol inhalers
  • the invention concerns a modified release pharmaceutical composition which comprises as active ingredient doxofylline, and a polymer selected from a pharmaceutically acceptable cellulose derivative, a pharmaceutically acceptable methacrylate derivative, their mixtures, and pharmaceutically acceptable salts thereof.
  • Doxofylline (or doxophylline) (7-(l,3-dioxalan-2-ylmethyl)-theophylline) has the following structural formula
  • active ingredient and is here also called “active ingredient” or “API” (Active Pharmaceutical Ingredient).
  • modified release pharmaceutical composition indicates a pharmaceutical composition that retains the active ingredient for a longer period of time than the conventional compositions and releases it slowly in order to maintain at length the plasmatic concentrations of the drug sufficient to exert the desired therapeutic effect.
  • Said formulation is here also called “BET” (Bioavailability Enhancing Technology) or “TOP” (Technology Optimized Performance) formulation.
  • polymer indicates, according to the present invention, a pharmaceutically acceptable release modulator polymer or copolymer, suitable for prolonging the release time of the active ingredient from the composition. Said polymer will be indicated below also simply as “release modulator polymer”.
  • pharmaceutically acceptable cellulose derivative indicates a derivative suitable for prolonging the release time of the drug from the composition, such as pharmaceutically acceptable cellulose esters and ethers, like methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and their salts.
  • pharmaceutically acceptable cellulose esters and ethers like methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxypropyl cellulose, carboxymethyl cellulose, cellulose acetate phthalate (CAP), cellulose acetate trimellitate (CAT), hydroxypropylmethyl cellulose phthalate, hydroxypropylmethyl cellulose acetate succinate, their mixtures and their salts.
  • pharmaceutically acceptable methacrylate derivative indicates a derivative suitable for prolonging the release time of the drug from the composition, for example the copolymer methacrylic acid/methyl methacrylate, the copolymer methacrylic acid/ethyl methacrylate, their mixtures and their salts.
  • bioequivalence is demonstrated if the 90% confidence interval of the AUC falls within an acceptance interval of 80% to 125%.
  • a preferred release modulator polymer according to the invention is a pharmaceutically acceptable cellulose derivative, advantageously selected from methyl cellulose, ethyl cellulose, hydroxyalkyl cellulose (such as hydroxypropylmethyl cellulose or hydroxypropyl cellulose) and their mixtures.
  • the composition of the invention is preferably a composition in the form of a dosage unit suitable for oral administration once a day, advantageously in the form of a tablet.
  • composition of the invention preferably also comprises excipients useful for the processing thereof, for example lubricating agents, such as magnesium stearate, filling agents, such as lactose, talc, microcrystalline cellulose, agents aiding compression and, if necessary or desired, other excipients such as aromatizers, sweeteners, preservatives, etc., well known to a person skilled in the art.
  • lubricating agents such as magnesium stearate
  • filling agents such as lactose, talc, microcrystalline cellulose
  • agents aiding compression such as lactose, talc, microcrystalline cellulose
  • other excipients such as aromatizers, sweeteners, preservatives, etc.
  • other excipients such as aromatizers, sweeteners, preservatives, etc.
  • a quantity of active ingredient between 550 and 800 mg, preferably between 600 and 750, more preferably between 625 and 700 mg, advantageously around 650 mg. It is understood that said dose can vary
  • the invention concerns a modified release composition which comprises as active ingredient approximately 650 mg of doxofylline and a release modulator polymer as defined above, advantageously in combination with a filling agent and/or a lubricant.
  • the release modulator polymers are used alone or mixed together, in quantities between 30 mg and 200 mg per tablet, preferably between 40 mg and 130 mg, more preferably between 120 and 130 mg; for example, 50, 100 or 125 mg, per dosage unit.
  • composition of the invention has proved to be particularly suitable for modified release of the active ingredient and with one single oral administration allows an effective haematic concentration of doxofylline to be maintained for 24 hours, while at the same time avoiding the excessive haematic peaks after the first and particularly after the second daily administration, which characterise the conventional compositions currently on sale.
  • composition of the invention advantageously also comprises a lubricant, for example magnesium stearate, for example in quantities between 1 and 15 mg, preferably between 3 and 10 mg, for example approximately 5 mg, per dosage unit.
  • a lubricant for example magnesium stearate, for example in quantities between 1 and 15 mg, preferably between 3 and 10 mg, for example approximately 5 mg, per dosage unit.
  • the preferred composition of the invention advantageously also comprises one or more filling agents, such as talc, lactose or microcrystalline cellulose, for example in total quantities of between 10 and 200 mg, preferably between 20 and 150 mg, advantageously 30, 50, 70 or 100 mg, per dosage unit; according to a first particularly preferred embodiment, the composition contains between 100 and 150 mg of filling agent; according to a second particularly preferred embodiment, the composition contains both talc and microcrystalline cellulose.
  • filling agents such as talc, lactose or microcrystalline cellulose
  • the composition comprises between 625 and 675 mg of doxofylline, between 100 and 150 mg of hydroxypropylmethyl cellulose, between 75 and 125 mg of microcrystalline cellulose, between 15 and 20 mg of talc and between 5 and 10 mg of magnesium stearate; more preferably, the composition comprises 650 mg of doxofylline, 125 mg of hydroxypropylmethyl cellulose, 100 mg of microcrystalline cellulose, 18 mg of talc and 7 mg of magnesium stearate.
  • composition of the invention is preferably in the form of a tablet and can be prepared by mixing the active ingredient, the release modulator polymer (or the mixture of polymers) and any other components and compressing them to an appropriate hardness, according to the methods known in the art.
  • the invention concerns use of the composition of the invention for the preparation of a bronchodilatory medication with antiinflammatory action for the treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the invention concerns use of the composition of the invention for the preparation of a medication for oral administration once a day only.
  • the invention concerns a method for the bronchodilatory treatment of all forms of asthma and chronic obstructive pulmonary disease (COPD) which comprises administration to a patient in need thereof of a therapeutically effective amount of the composition of the invention.
  • COPD chronic obstructive pulmonary disease
  • the invention concerns a method for improving bioavailability of doxofylline in a human being, which method comprises administering to said human being the composition of the invention; more in details, it concerns a method for obtaining in a human being a plasmatic level bioequivalent to that obtainable by administering twice a day an immediate release composition containing 400 mg of doxofylline (such as DOXOBID), which method comprises administering the composition of the invention once a day.
  • DOXOBID immediate release composition containing 400 mg of doxofylline
  • the invention comprises a process for preparation of the composition of the invention, in the form of tablets, which comprises:
  • phase (b) compressing is performed to obtain a tablet hardness of between 1 and 3 kg/cm 2 .
  • phase (d) in phase (d) a lubricating agent and/or a filling agent are mixed.
  • composition of the invention can also be formulated in the form of coated pellets.
  • the compositions of the invention have undergone various tests to assess their dissolution profile and stability, as well as their in vivo bioavailability. The tests conducted enabled us to conclude that the composition of the invention, in particular the preferred composition in the form of a tablet, as defined above, is stable and has an optimal dissolution profile for maintaining the haematic concentration of doxofylline effective for 24 hours.
  • compositions of the invention are therefore suitable for administration once a day only and, surprisingly, at a dosage even approximately 35% lower than the average daily dosage of the conventional formulations.
  • EXPERIMENTAL SECTION EXAMPLE 1 A modified release composition in tablet form is prepared which contains, for each tablet: • doxofylline 650.00 mg
  • microcrystalline cellulose 30.00 mg
  • a modified release composition in tablet form is prepared which contains, for each tablet:
  • a modified release composition in tablet form is prepared which contains, for each tablet:
  • microcrystalline cellulose 30.00 mg
  • a randomized, open-label, balanced, three-treatment, three-period, three sequence, single dose, crossover bioavailability study has been done in twelve healthy, adult, male, human subjects under fasting conditions using the 650 mg tablet of example 2 (Doxofylline SR 650) the 600 mg tablet of example 3 (Doxofylline SR 600) and the 400 mg tablet currently available on the market (DOXOBID); Doxofylline SR 650 and Doxofylline SR 600 have been administered once-a-day, whereas DOXOBID has been administered twice a day. Pharmacokinetic parameters have been calculated using KINETICA software. The area under the curve (AUC) was subjected to statistical treatment for significance by one-way analysis of variance ANOVA) using software, Jandel Scientif ⁇ ca, California.
  • FIG. 1 shows the data of Doxofylline SR 650 compared to that of DOXOBID whereas figure 2 shows the data of Doxofylline SR 600 compared to that of DOXOBID.
  • T/R relative bioavailabilities
  • Doxofylline SR 650 mg tablets Excellent results were obtained for Doxofylline SR 650 mg tablets.
  • the bioavailability of doxofylline was found to be about 0.98 and 0.92 times after administration of Doxofylline SR 650 mg and Doxofylline SR 600 mg tablets, respectively.
  • the bioavailability of Doxofylline 650 mg was almost identical to that of DOXOBID 400 mg twice daily, 12 hourly, therefore it could be possible to administer a single dose of Doxofylline SR 650 mg tablet instead of doxofylline 400 mg twice daily to treat symptoms associated with asthma and. COPD (chronic obstructive pulmonary disease).
  • DOXOBID immediate release tablets containing doxofylline 400mg for twice daily administration.
  • the open-label bioequivalence study was performed in 24 healthy, adult, male subjects. Each subject received 1 dose of the 650 mg tablet of example 2 (Doxofylline SR 650, herinafter indicated as DOXOTOP) and 2 doses of DOXOBID tablet at 0 and 12 hours. There was a wash-out period of 7 days between each study drug to prevent any carry-over effect. The order of the study drug administrations was randomized for all patients.
  • Doxofylline serum concentrations of DOXOTOP were tested 1 hour before drug administration and post-dose at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 3.00, 4.00, 6.00, 9.00, 12.00, 16.00 and 24.00 hours. At each time point 5 ml of blood was taken from the subject. Because the reference product (DOXOBID) is administered twice daily, the plasma levels should be tested at additional time points in order to measure the plasma peak after the second administration.
  • time points are measured, 1 hour before drug administration and post-dose at 0.25, 0.50, 0.75, 1.00, 1.25, 1.50, 1.75, 2.00, 3.00, 4.00, 6.00, 9.00, 12.00, 12.25, 12.50, 12.75, 13.00, 13.25, 13.50, 13.75, 14.00, 15.00, 16.00, 18.00, 21.00 and 24.00 hours.
  • 5 ml of blood was collected from the subject. All blood samples were collected via indwelling cannula placed in the forearm vein.
  • DOXOTOP 650mg
  • DOXOBID 400mg tablets twice daily This sustained release formulation therefore has an equal efficacy as the conventional tablets, but may have an even better safety profile since the peak serum concentrations are lower and less active drug is administered to the patient on a daily basis.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Photolithography (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Testing, Inspecting, Measuring Of Stereoscopic Televisions And Televisions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L’invention concerne une composition pharmaceutique à libération modifiée à base de doxofylline pour une administration une fois par jour seulement. La composition comprend de la doxofylline, en association avec un polymère choisi parmi un dérivé de cellulose pharmaceutiquement acceptable, un dérivé de méthacrylate pharmaceutiquement acceptable, leurs mélanges et des sels pharmaceutiquement acceptables de ceux-ci; la composition peut également comprendre des lubrifiants, comme du stéarate de magnésium, et des agents de remplissage, comme du lactose, du talc, de la cellulose microcristalline. La présente composition donne une concentration plasmatique bioéquivalente à celle obtenue par la composition à libération immédiate actuellement offerte sur le marché, mais à une dose plus faible de l’ingrédient actif.
EP09721101A 2008-03-10 2009-03-06 Composition à libération modifiée comprenant de la doxofylline Withdrawn EP2262485A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/000554 WO2009112874A1 (fr) 2008-03-10 2008-03-10 Composition à libération modifiée comprenant de la doxofylline
PCT/EP2009/052675 WO2009112436A1 (fr) 2008-03-10 2009-03-06 Composition à libération modifiée comprenant de la doxofylline

Publications (1)

Publication Number Publication Date
EP2262485A1 true EP2262485A1 (fr) 2010-12-22

Family

ID=40084194

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09721101A Withdrawn EP2262485A1 (fr) 2008-03-10 2009-03-06 Composition à libération modifiée comprenant de la doxofylline

Country Status (7)

Country Link
EP (1) EP2262485A1 (fr)
KR (1) KR101697773B1 (fr)
AU (1) AU2009224801B2 (fr)
BR (1) BRPI0906158B8 (fr)
IT (1) ITMI20080798A1 (fr)
MX (2) MX2008010233A (fr)
WO (2) WO2009112874A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150063040A (ko) * 2012-09-26 2015-06-08 유로드러그 레버러토리즈 비. 브이. 간 질환의 치료에 사용하기 위한 메타독신 및 메타독신 연장 방출성 제제
CN103524503B (zh) * 2013-10-29 2014-08-06 天津梅花医药有限公司 多索茶碱半水化合物
CN110898019A (zh) * 2019-12-19 2020-03-24 上海宣泰海门药业有限公司 多索茶碱片及其制备方法
CN119909028B (zh) * 2025-01-21 2025-10-14 福安药业集团宁波天衡制药有限公司 一种多索茶碱片及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101028254A (zh) * 2007-04-05 2007-09-05 合肥合源医药科技有限公司 一种多索茶碱缓释制剂及其制备方法
CN101069688A (zh) * 2006-05-10 2007-11-14 鲁南制药集团股份有限公司 含有茶碱类药物和维生素k的药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE34300T1 (de) * 1981-07-15 1988-06-15 Key Pharma Theophyllin mit verlaengerter abgabe.
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
US4837032A (en) * 1986-02-04 1989-06-06 Farval Ag Theophylline sustained release tablet
US4710384A (en) * 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5196203A (en) * 1989-01-06 1993-03-23 F. H. Faulding & Co. Limited Theophylline dosage form
PT797987E (pt) * 1994-12-19 2004-02-27 Daiichi Seiyaku Co Preparacao granular de libertacao controlada e processo para a sua preparacao
US20040087653A1 (en) * 2002-05-16 2004-05-06 Manning Pamela T. Methods for the treatment of respiratory diseases and conditions with a selective iNOS inhibitor and a PDE inhibitor and compositions therefor
JP4792974B2 (ja) * 2003-12-25 2011-10-12 小野薬品工業株式会社 アゼチジン環化合物およびその医薬
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
ES2366375T3 (es) * 2005-02-22 2011-10-19 Pfizer, Inc. Derivados de oxiindol, como agonistas del receptor 5-ht4.
WO2007120485A2 (fr) * 2006-03-30 2007-10-25 Cinergen, Llc Procédés de traitement de la douleur avec des alkylxanthines et des antiépileptiques et compositions à utiliser à cet effet
WO2008033351A2 (fr) * 2006-09-11 2008-03-20 Theraquest Biosciences, Inc. Formulations multimode de libération prolongée et résistantes à l'abus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101069688A (zh) * 2006-05-10 2007-11-14 鲁南制药集团股份有限公司 含有茶碱类药物和维生素k的药物组合物
CN101028254A (zh) * 2007-04-05 2007-09-05 合肥合源医药科技有限公司 一种多索茶碱缓释制剂及其制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2009112436A1 *

Also Published As

Publication number Publication date
BRPI0906158B1 (pt) 2021-01-05
BRPI0906158B8 (pt) 2021-05-25
MX2010009917A (es) 2010-12-21
ITMI20080798A1 (it) 2009-09-11
AU2009224801A1 (en) 2009-09-17
MX2008010233A (es) 2009-11-10
AU2009224801B2 (en) 2014-06-05
BRPI0906158A2 (pt) 2017-07-18
KR101697773B1 (ko) 2017-01-18
WO2009112874A1 (fr) 2009-09-17
KR20100124860A (ko) 2010-11-30
WO2009112436A1 (fr) 2009-09-17

Similar Documents

Publication Publication Date Title
TWI241911B (en) Sustained release ranolazine formulations
JP2568202B2 (ja) 制御放出型ジヒドロコデイン組成物
US20040202716A1 (en) Composition
MX2008015359A (es) Forma de dosis farmaceutica de liberacion sostenida que contiene fenilefrina.
US8604084B2 (en) Method
JP2001517626A (ja) 呼吸疾患を治療するための組成物及び方法
WO2014209087A1 (fr) Préparation composite pour gélule pharmaceutique comprenant du tadalafil et de la tamsulosine
AU2009224801B2 (en) Modified release composition comprising doxofylline
US20190209551A1 (en) Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer
PT1807156T (pt) Novas formulações farmacêuticas úteis no tratamento de insónia
RU2256454C2 (ru) Способы получения фармацевтических композиций алкалоидов спорыньи с пролонгированным действием, характеризующихся улучшенной биодоступностью, и содержащие указанные алкалоиды композиции
EP1465607B1 (fr) Compositions pharmaceutiques a liberation modifiee
US20060147526A1 (en) Pharmaceutical formulations comprising ß-2 adrenoreceptor agonists and xanthines
CN115105478B (zh) 一种拉考沙胺药物组合物、其制备方法及应用
JP2021088591A (ja) 浸食マトリックス中に１またはそれ以上のフマル酸エステルを含む医薬製剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20100927

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150928

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160209